Topic
1 story, newest first.
AstraZeneca has made a non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, a company specializing in treatments for rare forms of obesity. The offer values Rhythm at about $124 per share, including potential milestone payments.